(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 14.17%
Live Chart Being Loaded With Signals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States...
Stats | |
---|---|
今日成交量 | 179 194 |
平均成交量 | 234 027 |
市值 | 81.26M |
EPS | €0 ( 2024-03-27 ) |
下一个收益日期 | ( €-0.240 ) 2024-05-08 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.660 |
ATR14 | €0.0140 (1.03%) |
音量 相关性
Inflarx NV 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Inflarx NV 相关性 - 货币/商品
Inflarx NV 财务报表
Annual | 2023 |
营收: | €61 795.00 |
毛利润: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2023 |
营收: | €61 795.00 |
毛利润: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2022 |
营收: | €0 |
毛利润: | €-585 852 (0.00 %) |
EPS: | €-0.610 |
FY | 2021 |
营收: | €0.00 |
毛利润: | €0.00 (0.00 %) |
EPS: | €-1.100 |
Financial Reports:
No articles found.
Inflarx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。